Taho Pharmaceuticals Ltd. (TPEX:6467)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
105.00
-1.00 (-0.94%)
At close: Jul 29, 2026

Taho Pharmaceuticals Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2017
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '17
Revenue
5.428.41-1.076.3612.4
Revenue Growth
-33.03%---83.23%-48.73%-65.56%
Gross Profit
3.775.41--0.075.06-1.14
Operating Income
-236.7-220.14-170.13-121.1-66.71-107.25
Net Income
-232.53-214.4-167.44-120.68-66.3-137.14
Earnings Per Share
-4.49-4.16-3.69-3.12-1.84-2.62
EPS Growth
------

Revenue by Geography

Fiscal YearFY 2025
Period EndingDec '25
Japan
0.08
United State
8.33
Total
8.41

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2017
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '17
Cash & Investments
347.19389.98495.87229.77106.3128.63
Total Debt
9.9511.3116.6521.62-0.91
Net Cash (Debt)
337.25378.66479.22208.15106.3127.72
Net Cash Growth
-10.94%-20.98%130.22%95.82%-16.77%-42.91%
Net Cash Per Share
6.527.3610.565.372.962.44

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2017
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '17
Operating Cash Flow
-195.36-203.73-156.91-104.22-62.78-136.46
Capital Expenditures
-4.93-5.41-8.82-2.89-0.83-1.97
Free Cash Flow
-200.29-209.14-165.73-107.1-63.61-138.44
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2017
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '17
Gross Margin
69.51%64.29%--6.75%79.52%-9.16%
Operating Margin
-4366.30%-2617.59%--11359.94%-1049.20%-864.87%
Pretax Margin
-4289.49%-2549.32%--11321.11%-1042.75%-1105.89%
Profit Margin
-4289.48%-2549.32%--11321.11%-1042.75%-1105.89%
FCF Margin
-3694.78%-2486.80%--10047.00%-1000.49%-1116.35%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2017
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '17
PS Ratio
1014.38681.34---49.65